Skip to content
Back to meeting Original
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)· @TiansterZhang · X·· 3 days agoScore70
Body

@DrIacovelli with phase 2 #PEPE trial - pembrolizumab w met directed treatment vs MDT in oligomet #kidneycancer — meets 1o PFS endpoint. Congrats on well done IIT. My practice is pembro after consolidative tx & great to see prospective supporting data.
@oncoalert #ESMO26 @myESMO

84 views · 4 likes · 5 reposts · 0 replies

Source: Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.